1. Home
  2. OCGN vs DRDB Comparison

OCGN vs DRDB Comparison

Compare OCGN & DRDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCGN
  • DRDB
  • Stock Information
  • Founded
  • OCGN 2013
  • DRDB 2024
  • Country
  • OCGN United States
  • DRDB United States
  • Employees
  • OCGN N/A
  • DRDB N/A
  • Industry
  • OCGN Biotechnology: Biological Products (No Diagnostic Substances)
  • DRDB
  • Sector
  • OCGN Health Care
  • DRDB
  • Exchange
  • OCGN Nasdaq
  • DRDB Nasdaq
  • Market Cap
  • OCGN 321.7M
  • DRDB 315.3M
  • IPO Year
  • OCGN N/A
  • DRDB 2024
  • Fundamental
  • Price
  • OCGN $1.39
  • DRDB $10.29
  • Analyst Decision
  • OCGN Strong Buy
  • DRDB
  • Analyst Count
  • OCGN 3
  • DRDB 0
  • Target Price
  • OCGN $6.00
  • DRDB N/A
  • AVG Volume (30 Days)
  • OCGN 2.6M
  • DRDB 57.8K
  • Earning Date
  • OCGN 11-07-2025
  • DRDB 01-01-0001
  • Dividend Yield
  • OCGN N/A
  • DRDB N/A
  • EPS Growth
  • OCGN N/A
  • DRDB N/A
  • EPS
  • OCGN N/A
  • DRDB N/A
  • Revenue
  • OCGN $4,754,000.00
  • DRDB N/A
  • Revenue This Year
  • OCGN N/A
  • DRDB N/A
  • Revenue Next Year
  • OCGN N/A
  • DRDB N/A
  • P/E Ratio
  • OCGN N/A
  • DRDB $588.24
  • Revenue Growth
  • OCGN N/A
  • DRDB N/A
  • 52 Week Low
  • OCGN $0.52
  • DRDB $9.87
  • 52 Week High
  • OCGN $1.33
  • DRDB $10.43
  • Technical
  • Relative Strength Index (RSI)
  • OCGN 83.73
  • DRDB N/A
  • Support Level
  • OCGN $1.00
  • DRDB N/A
  • Resistance Level
  • OCGN $1.25
  • DRDB N/A
  • Average True Range (ATR)
  • OCGN 0.06
  • DRDB 0.00
  • MACD
  • OCGN 0.04
  • DRDB 0.00
  • Stochastic Oscillator
  • OCGN 92.69
  • DRDB 0.00

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

About DRDB Roman DBDR Acquisition Corp. II Ordinary shares

Roman DBDR Acquisition Corp II is a blank check company.

Share on Social Networks: